INSMED INC (INSM) Spending and interest coverage
- R&D / revenue · 12 months: Value 75.67%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 13.84%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 75.67% | Research and development expense / revenue. Period ending 2026-06-30. $860.85M ÷ $1.14B × 100 ≈ 75.67% |
| Stock-based compensation / revenue · 12 months | 13.84% | Share-based compensation / revenue. Period ending 2026-06-30. $157.48M ÷ $1.14B × 100 ≈ 13.84% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 860.85M USD | Research and Development Expense |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 157.48M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -840.62M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $860.85M | $1.14B | $157.48M | $-840.62M | (m) | 75.67% | 13.84% | (m) | (m) |
| 2026-03-31 | $828.00M | $819.56M | $159.20M | $-1.15B | (m) | 101.03% | 19.43% | (m) | (m) |
| 2025-12-31 | $771.09M | $606.42M | $152.71M | $-1.25B | $83.80M | 127.15% | 25.18% | -14.88× | Reported |
| 2025-09-30 | $695.91M | $447.02M | $140.22M | $-1.16B | (m) | 155.68% | 31.37% | (m) | (m) |
| 2025-06-30 | $660.30M | $398.11M | $134.34M | $-1.00B | $85.42M | 165.86% | 33.74% | -11.76× | Reported |
| 2025-03-31 | $629.86M | $381.03M | $114.65M | $-980.89M | $85.44M | 165.30% | 30.09% | -11.48× | Reported |
| 2024-12-31 | $598.37M | $363.71M | $96.83M | $-878.25M | $84.91M | 164.52% | 26.62% | -10.34× | Reported |
| 2024-09-30 | $555.67M | $342.96M | $90.26M | $-826.11M | $84.15M | 162.02% | 26.32% | -9.82× | Reported |
| 2024-06-30 | $514.01M | $328.61M | $84.71M | $-760.35M | $83.38M | 156.42% | 25.78% | -9.12× | Reported |
| 2024-03-31 | $564.23M | $315.49M | $79.78M | $-706.97M | $82.73M | 178.84% | 25.29% | -8.55× | Reported |
| 2023-12-31 | $571.01M | $305.21M | $74.78M | $-709.63M | $81.69M | 187.09% | 24.50% | -8.69× | Reported |
| 2023-09-30 | $558.75M | $280.81M | $69.75M | $-682.83M | $77.36M | 198.97% | 24.84% | -8.83× | Reported |
| 2023-06-30 | $549.47M | $269.47M | $65.41M | $-662.86M | $60.42M | 203.91% | 24.27% | -10.97× | Reported |
| 2023-03-31 | $441.03M | $257.46M | $61.31M | $-515.65M | $43.16M | 171.30% | 23.81% | -11.95× | Reported |
| 2022-12-31 | $397.52M | $245.36M | $57.69M | $-457.32M | $26.45M | 162.02% | 23.51% | -17.29× | Reported |
| 2022-09-30 | $349.11M | $242.18M | $54.26M | $-404.92M | $21.35M | 144.15% | 22.40% | -18.97× | Reported |
| 2022-06-30 | $319.58M | $221.21M | $50.83M | $-380.84M | $29.24M | 144.47% | 22.98% | -13.02× | Reported |
| 2022-03-31 | $295.71M | $201.35M | $48.31M | $-381.09M | $36.20M | 146.86% | 23.99% | -10.53× | Reported |
| 2021-12-31 | $272.74M | $188.46M | $46.02M | $-375.09M | $40.47M | 144.72% | 24.42% | -9.27× | Reported |
| 2021-09-30 | $264.21M | $173.75M | $43.28M | $-370.55M | $36.62M | 152.06% | 24.91% | -10.12× | Reported |
| 2021-06-30 | $235.27M | $170.64M | $39.96M | $-323.16M | $32.56M | 137.88% | 23.42% | -9.92× | Reported |
| 2021-03-31 | $206.36M | $167.77M | $37.69M | $-288.71M | $29.71M | 123.01% | 22.47% | -9.72× | Reported |
| 2020-12-31 | $181.16M | $164.41M | $36.16M | $-265.23M | $29.56M | 110.18% | 21.99% | -8.97× | Reported |
| 2020-09-30 | $145.97M | $168.71M | $33.27M | $-217.78M | $29.41M | 86.53% | 19.72% | -7.40× | Reported |
| 2020-06-30 | $138.90M | $163.95M | $31.15M | $-218.04M | $29.07M | 84.72% | 19.00% | -7.50× | Reported |
| 2020-03-31 | $136.69M | $151.43M | $29.04M | $-226.09M | $28.39M | 90.27% | 19.18% | -7.96× | Reported |
| 2019-12-31 | $131.71M | $136.47M | $26.97M | $-235.25M | $27.70M | 96.51% | 19.76% | -8.49× | Reported |
| 2019-09-30 | $139.01M | $100.59M | $27.12M | $-275.88M | $27.02M | 138.19% | 26.96% | -10.21× | Reported |
| 2019-06-30 | $144.20M | $61.71M | $28.23M | $-303.38M | $26.85M | 233.68% | 45.74% | -11.30× | Reported |
| 2019-03-31 | $146.39M | $31.74M | $27.50M | $-314.10M | $26.56M | 461.25% | 86.66% | -11.83× | Reported |
| 2018-12-31 | $145.28M | $9.84M | $26.24M | $-307.34M | $25.47M | 1477.20% | 266.80% | -12.07× | Reported |
| 2018-09-30 | $139.31M | $0.00 | $24.95M | $-284.97M | $20.27M | (m) | (m) | -14.06× | Reported |
| 2018-06-30 | $126.44M | $0.00 | $21.79M | $-245.07M | $15.09M | (m) | (m) | -16.24× | Reported |
| 2018-03-31 | $117.59M | $0.00 | $19.71M | $-215.70M | $10.09M | (m) | (m) | -21.37× | Reported |
| 2017-12-31 | $109.75M | $0.00 | $18.07M | $-188.92M | $5.92M | (m) | (m) | -31.89× | Reported |
| 2017-09-30 | $130.67M | (m) | $17.49M | $-190.62M | $5.94M | (m) | (m) | -32.08× | Reported |
| 2017-06-30 | $127.43M | (m) | $17.80M | $-183.68M | $5.21M | (m) | (m) | -35.22× | Reported |
| 2017-03-31 | $124.43M | (m) | $17.85M | $-176.30M | $4.35M | (m) | (m) | -40.53× | Reported |
| 2016-12-31 | $122.72M | (m) | $18.04M | $-173.40M | $3.50M | (m) | (m) | -49.57× | Reported |
| 2016-09-30 | $87.50M | (m) | $17.71M | $-138.94M | $2.74M | (m) | (m) | -50.73× | Reported |
| 2016-06-30 | $83.28M | (m) | $16.46M | $-132.03M | $2.69M | (m) | (m) | -48.99× | Reported |
| 2016-03-31 | $77.66M | (m) | $15.29M | $-123.85M | $2.79M | (m) | (m) | -44.41× | Reported |
| 2015-12-31 | $74.28M | (m) | $15.59M | $-117.49M | $2.89M | (m) | (m) | -40.67× | Reported |
| 2015-09-30 | $69.43M | (m) | $14.49M | $-107.97M | $2.79M | (m) | (m) | -38.77× | Reported |
| 2015-06-30 | $65.41M | (m) | $13.95M | $-101.13M | $2.65M | (m) | (m) | -38.10× | Reported |
| 2015-03-31 | $62.10M | (m) | $13.49M | $-95.99M | $2.53M | (m) | (m) | -37.93× | Reported |
| 2014-12-31 | $56.29M | (m) | $11.33M | $-87.36M | $2.42M | (m) | (m) | -36.18× | Reported |
| 2014-09-30 | $51.12M | (m) | $10.85M | $-79.89M | $2.40M | (m) | (m) | -33.22× | Reported |
| 2014-06-30 | $48.01M | (m) | $9.05M | $-73.33M | $2.34M | (m) | (m) | -31.39× | Reported |
| 2014-03-31 | $45.30M | (m) | $10.07M | $-58.78M | $2.38M | (m) | (m) | -24.75× | Reported |
| 2013-12-31 | $44.28M | $11.50M | $8.67M | $-55.02M | $2.41M | 385.03% | 75.37% | -22.81× | Reported |
| 2013-09-30 | $46.24M | $11.50M | $7.87M | $-55.26M | $2.34M | 402.13% | 68.46% | -23.61× | Reported |
| 2013-06-30 | $39.86M | $11.50M | $6.92M | $-47.77M | $2.04M | 346.57% | 60.18% | -23.45× | Reported |
| 2013-03-31 | $35.38M | (m) | $3.44M | $-49.48M | $1.40M | (m) | (m) | -35.24× | Reported |
| 2012-12-31 | $29.78M | $0.00 | $2.98M | $-42.44M | $763.00K | (m) | (m) | -55.62× | Reported |
| 2012-09-30 | $24.07M | $1.40M | $2.03M | $-35.47M | $226.00K | 1715.68% | 144.40% | -156.95× | Reported |
| 2012-06-30 | $25.46M | $1.84M | $1.96M | $-61.08M | $6.00K | 1385.42% | 106.64% | -10179.33× | Reported |
| 2012-03-31 | $26.64M | $2.82M | $1.93M | $-61.57M | $8.00K | 946.16% | 68.43% | -7696.00× | Reported |
| 2011-12-31 | $27.92M | $4.42M | $1.60M | $-61.72M | $10.00K | 632.04% | 36.20% | -6171.90× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $4.76M | $6.92M | $366.00K | $-8.09M | $109.00K | 68.73% | 5.29% | -74.24× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $9.21M | $10.37M | $2.54M | $-8.67M | $781.00K | 88.76% | 24.51% | -11.11× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |